To the Editor.
—5-Azacitidine is a pyrimidine analog that has demonstrated activity as an antileukemic agent and as a treatment for some hemoglobinopathies.1 It has been investigated as a treatment modality for myelodysplastic syndromes (Cancer and Leukemia Group B [CALG B] Protocol 8921: A Phase II Study of 5-Azacitidine in Myelodysplastic Syndromes). In previous studies, no cutaneous complicationshave been reported from the subcutaneous administration of 5-azacitidine.2We describe two patients with myelodysplastic syndromes in whom reproducible cutaneous reactions developed at injection sites of subcutaneous 5-azacitidine.
Report of Cases.
—Case 1.—A 45-year-old white man was hospitalized for treatment of refractory anemia with excess blast forms in transformation. Chemotherapy had been started with 5-azacitidine given at a dose of 180 mg/d divided into two subcutaneous injection sites for a scheduled 7-day course. No other chemotherapy was being administered. On the third day of treatment, it was noted that the
Goldsmith SM, Sherertz EF, Powell BL, Hurd DD. Cutaneous Reactions to Azacitidine. Arch Dermatol. 1991;127(12):1847–1848. doi:10.1001/archderm.1991.04520010089020
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.